Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Wiley full text link Wiley Free PMC article
Full text links

Actions

Share

Review
.2020 Jul;160(3):223-232.
doi: 10.1111/imm.13222.

The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world

Affiliations
Review

The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world

Hannah R Sharpe et al. Immunology.2020 Jul.

Abstract

Since the first World Health Organization notification on 31 December 2019, coronavirus disease 2019 (COVID-19), the respiratory disease caused by the coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been responsible for over four million confirmed infections and almost 300 000 deaths worldwide. The pandemic has led to over half of the world's population living under lockdown conditions. To allow normal life to resume, public health interventions will be needed to prevent further waves of infections as lockdown measures are lifted. As one of the most effective countermeasures against infectious diseases, an efficacious vaccine is considered crucial to containing the COVID-19 pandemic. Following the publication of the genome sequence of SARS-CoV-2, vaccine development has accelerated at an unprecedented pace across the world. Here we review the different platforms employed to develop vaccines, the standard timelines of development and how they can be condensed in a pandemic situation. We focus on vaccine development in the UK and vaccines that have entered clinical trials around the world.

Keywords: coronavirus disease 2019; severe acute respiratory syndrome coronavirus-2; vaccine.

© 2020 The Authors. Immunology published by John Wiley & Sons Ltd.

PubMed Disclaimer

Conflict of interest statement

Teresa Lambe is named as an inventor on a patent application covering a SARS‐CoV‐2 (nCoV‐19) vaccine. The remaining authors declare no competing interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID‐19): a clinical update. Front Med 2020; 14:126–135. - PMC - PubMed
    1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W et al A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579:270–3. - PMC - PubMed
    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727–33. - PMC - PubMed
    1. Wang JT, Chang SC. Severe acute respiratory syndrome. Curr Opin Infect Dis 2004; 17:143–8. - PubMed
    1. Kapp C. WHO lowers figures on SARS infections. Lancet 2003; 362:1207. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

Full text links
Wiley full text link Wiley Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp